Opportunities for Partnering
Seeking like-minded science partners
Strategic partnerships can improve the chances of delivering life-changing medicines to patients. We're constantly seeking opportunities for early-stage biologics and associated technologies, and we want to connect with partners whose areas of interest match our own.
Our areas of Interest
A targeted approach
Eliminating cancer is our goal. That focus includes pursuing innovative technologies that can do this in more effective and targeted ways, including effector-enhanced, polyspecific, and toxin-carrying antibodies. Our portfolio is robust and growing—with programs in immuno-oncology, angiogenesis inhibition, ADCs and tumor stem cells.
- Immune-mediated therapies
- Tumor-associated antigens
- Cancer stem cells
- Oncolytic viruses
- Engineered cellular therapies
Respiratory, Inflammation and Autoimmunity
Our Respiratory, Inflammation and Autoimmunity portfolio is rich and diverse. From pioneering innovative research to leveraging industry-leading technology, we’re delivering important and groundbreaking therapy to patients.
- Respiratory diseases
- Rheumatologic autoimmune diseases
- Neuroinflammatory autoimmune diseases
- Inflammatory bowel diseases
Cardiovascular, Renal and Metabolism
Broadening our vision
Science has shown us that biologics have a role in the pathophysiology of Cardiovascular, Renal and Metabolic Diseases. Today, our unique capabilities and technology platforms are helping us to discover and develop novel and differentiated drugs to treat diabetic nephropathy, obesity, and cardiovascular disease.
- Diabetes (Type 1 and 2)
- Chronic kidney disease
- Non-Alcoholic steatohepatitis
- Cardiovascular disease
Prescription for the future
We know our bacteria, fungi and viruses, and we’re on a mission to explore ways of bringing biologic technology to the most challenging infectious disease needs of today and tomorrow. Our position in the industry is unique, as we investigate the intersecting roles of biologics, small molecules and vaccines.
- Viral infections
- Multi-drug resistant ESKAPE pathogens
- Other serious bacterial pathogens
Open for Opportunity
The MedImmune Partnering Team is responsible for all early stage (Phase 1 and earlier) biologics assets and associated technologies for AstraZeneca and MedImmune. For small molecule and late-stage contacts, visit the AstraZeneca Partnering page.
Sir Aaron Klug Building, Granta Park Cambridge, CB21 6GH, UK
One MedImmune Way Gaithersburg, MD 20878
South San Francisco, CA:
121 Oyster Point Blvd, South San Francisco, CA 94080
Our partnering Process
Our partnering experts will facilitate an initial review and evaluation of potential opportunities – working closely with MedImmune scientists, commercial experts and other relevant parties in order to determine if the opportunity warrants further exploration.
If based on the initial evaluation, the partnering team determines an opportunity should be explored further, an initial business case is developed with an internal team of experienced functional experts. This business case will be used to help inform the initial negotiations.
In collaboration with your partnering team and scientist, your designated MedImmune partnering team will work with you to establish initial deal terms.
A specialized deal team will work with you to conduct a thorough evaluation, assessing technical, finance, legal, and other aspects to ensure the opportunity is well understood prior to fully engaging in the detailed negotiations.
A team of experts will work with you to rapidly negotiate the deal and ensure that the terms are flexible and focused on creating a win-win situation for all parties.
Prior to closing a deal, our Alliance Management team will become fully engaged to ensure a rapid and seamless implementation and to ensure you have a designated Alliance Manager who will manage the relationship on an ongoing basis.